1
|
Zhang A, Seiss K, Laborde L, Palacio-Ramirez S, Guthy D, Lanter M, Lorber J, Vulpetti A, Arista L, Zoller T, Radimerski T, Thoma C, Hebach C, Tschantz WR, Karpov A, Hollingworth GJ, D'Alessio JA, Ferretti S, Burger MT. Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates. Bioconjug Chem 2024; 35:140-146. [PMID: 38265691 DOI: 10.1021/acs.bioconjchem.3c00535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2024]
Abstract
Antibody-drug conjugates (ADCs) are an established modality that allow for targeted delivery of a potent molecule, or payload, to a desired site of action. ADCs, wherein the payload is a targeted protein degrader, are an emerging area in the field. Herein we describe our efforts of delivering a Bruton's tyrosine kinase (BTK) bifunctional degrader 1 via a CD79b mAb (monoclonal antibody) where the degrader is linked at the ligase binding portion of the payload via a cleavable linker to the mAb. The resulting CD79b ADCs, 3 and 4, exhibit in vitro degradation and cytotoxicity comparable with that of 1, and ADC 3 can achieve more sustained in vivo degradation than intravenously administered 1 with markedly reduced systemic exposure of the payload.
Collapse
Affiliation(s)
- Alan Zhang
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | - Katherine Seiss
- Oncology Biotherapeutics, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | - Laurent Laborde
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Sebastian Palacio-Ramirez
- Novartis Biologics Center, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | - Daniel Guthy
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Mylene Lanter
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Julien Lorber
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Anna Vulpetti
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Luca Arista
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Thomas Zoller
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | | | - Claudio Thoma
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - Christina Hebach
- Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | - William R Tschantz
- Novartis Biologics Center, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | - Alexei Karpov
- Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland
| | | | - Joseph A D'Alessio
- Oncology Biotherapeutics, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| | | | - Matthew T Burger
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States
| |
Collapse
|
2
|
Liu SQ, Grantham A, Landry C, Granda B, Chopra R, Chakravarthy S, Deutsch S, Vogel M, Russo K, Seiss K, Tschantz WR, Rejtar T, Ruddy DA, Hu T, Aardalen K, Wagner JP, Dranoff G, D'Alessio JA. A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy. Cancer Immunol Res 2020; 9:34-49. [PMID: 33177106 DOI: 10.1158/2326-6066.cir-20-0080] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Revised: 06/26/2020] [Accepted: 10/22/2020] [Indexed: 11/16/2022]
Abstract
CD3-bispecific antibodies represent an important therapeutic strategy in oncology. These molecules work by redirecting cytotoxic T cells to antigen-bearing tumor cells. Although CD3-bispecific antibodies have been developed for several clinical indications, cases of cancer-derived resistance are an emerging limitation to the more generalized application of these molecules. Here, we devised whole-genome CRISPR screens to identify cancer resistance mechanisms to CD3-bispecific antibodies across multiple targets and cancer types. By validating the screen hits, we found that deficiency in IFNγ signaling has a prominent role in cancer resistance. IFNγ functioned by stimulating the expression of T-cell killing-related molecules in a cell type-specific manner. By assessing resistance to the clinical CD3-bispecific antibody flotetuzumab, we identified core fucosylation as a critical pathway to regulate flotetuzumab binding to the CD123 antigen. Disruption of this pathway resulted in significant resistance to flotetuzumab treatment. Proper fucosylation of CD123 was required for its normal biological functions. In order to treat the resistance associated with fucosylation loss, flotetuzumab in combination with an alternative targeting CD3-bispecific antibody demonstrated superior efficacy. Together, our study reveals multiple mechanisms that can be targeted to enhance the clinical potential of current and future T-cell-engaging CD3-bispecific antibody therapies.
Collapse
Affiliation(s)
- Si-Qi Liu
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | - Alyssa Grantham
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | - Casey Landry
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | - Brian Granda
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | - Rajiv Chopra
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | | | - Sabine Deutsch
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Markus Vogel
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Katie Russo
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | - Katherine Seiss
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | | | - Tomas Rejtar
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | - David A Ruddy
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | - Tiancen Hu
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | - Kimberly Aardalen
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | - Joel P Wagner
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | - Glenn Dranoff
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | | |
Collapse
|
3
|
Tam A, Zambrowski M, Seiss K, Liu SQ, Abrams T, Caponigro G, Tschantz W, Campbell J, DAlessio T, Sheng Q. Abstract 4743: Using genome-wide CRISPR screen to understand resistance mechanisms to PCA062, a P-cadherin targeting antibody-drug conjugate. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-4743] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
P-cadherin (PCAD) is a member of the cadherin family that mediates calcium dependent cell-cell contacts in adherens-type junctions of epithelium. Expression of P-cadherin is high in malignant tumors of epithelial origin, such as breast, esophagus, head and neck cancers, but low in normal tissues. This expression pattern makes P-cadherin a potential good target for antibody-drug conjugates (ADCs). PCA062 is a first-in-class antibody drug conjugate targeting P-cadherin. PCA062 consists of a fully human anti-P-cadherin antibody of the IgG1/κ subtype, a non-cleavable bi-functional linker (SMCC) and a maytansine-derived cytotoxic payload (DM1, with a target average drug to antibody ratio (DAR) of 3.8).
PCA062 activity was examined in a collection of cell lines expressing high level of PCAD. A subset of these PCAD high cell lines are resistant to PCA062 treatment while they remain sensitive to DM1, suggesting defects in the process of PCA062 uptake or the processing and release of DM1 into the cytoplasmic compartment. PCA062 internalization rate was measured by the uptake of a fluorescent dye labeled anti-PCAD antibody (CQY684, the Ab portion of PCA062) in both PCA062 sensitive and resistant lines. PCA062 resistant lines show slower CQY684 internalization as compared to PCA062 sensitive lines, indicating a defect in ADC internalization may contribute to PCA062 resistance. To explore additional resistance mechanisms to PCA062 as well as to find critical components for PCA062 internalization, a genome wide CRISPR screen was performed in PCA062 sensitive HCC1954 and in PCA062 resistant KYSE510 cell line in the presence and absence of PCA062 and DM1 to look for genes that when knocked out may specifically modulate PCA062 sensitivity. The multi-drug resistant gene MRP1 is a strong hit for PCA062 sensitization in both PCA062 resistant KYSE510 and PCA062 sensitive HCC1954 cells. Lysosomal transporter SLC46A3 and Saga transcription complex components are strong rescue hits for PCA062 in HCC1954. These data suggest that in addition to target expression level and cell intrinsic sensitivity to payload, genes involved in ADC internalization and payload cytoplasmic accumulation will also impact tumor cell sensitivity to ADCs.
Citation Format: Angela Tam, Mark Zambrowski, Katherine Seiss, Si-Qi Liu, Tinya Abrams, Giordano Caponigro, William Tschantz, Jennifer Campbell, Tony DAlessio, Qing Sheng. Using genome-wide CRISPR screen to understand resistance mechanisms to PCA062, a P-cadherin targeting antibody-drug conjugate [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4743.
Collapse
Affiliation(s)
- Angela Tam
- Novartis Institutes for BioMedical Research, Cambridge, MA
| | | | | | - Si-Qi Liu
- Novartis Institutes for BioMedical Research, Cambridge, MA
| | - Tinya Abrams
- Novartis Institutes for BioMedical Research, Cambridge, MA
| | | | | | | | - Tony DAlessio
- Novartis Institutes for BioMedical Research, Cambridge, MA
| | - Qing Sheng
- Novartis Institutes for BioMedical Research, Cambridge, MA
| |
Collapse
|
4
|
Buzon MJ, Sun H, Li C, Shaw A, Seiss K, Ouyang Z, Martin-Gayo E, Leng J, Henrich TJ, Li JZ, Pereyra F, Zurakowski R, Walker BD, Rosenberg ES, Yu XG, Lichterfeld M. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med 2014; 20:139-42. [PMID: 24412925 PMCID: PMC3959167 DOI: 10.1038/nm.3445] [Citation(s) in RCA: 337] [Impact Index Per Article: 33.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2013] [Accepted: 12/09/2013] [Indexed: 12/11/2022]
Abstract
Cellular HIV-1 reservoirs that persist despite antiretroviral treatment are incompletely defined. We show that during suppressive antiretroviral therapy, CD4+ T memory stem cells (TSCM) harbor high per-cell levels of HIV-1 DNA, and make increasing contributions to the total viral CD4+ T cell reservoir over time. Moreover, phylogenetic studies suggested long-term persistence of viral quasispecies in CD4+ TSCM cells. Thus, HIV-1 may exploit stem cell characteristics of cellular immune memory to promote long-term viral persistence.
Collapse
Affiliation(s)
- Maria J Buzon
- 1] Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
| | - Hong Sun
- 1] Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA. [2] Key Laboratory of AIDS Immunology, Department of Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province, China
| | - Chun Li
- Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
| | - Amy Shaw
- Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
| | - Katherine Seiss
- Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
| | - Zhengyu Ouyang
- Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
| | | | - Jin Leng
- Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
| | - Timothy J Henrich
- Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Jonathan Z Li
- Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Florencia Pereyra
- 1] Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA. [2] Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Ryan Zurakowski
- Department of Electrical and Computer Engineering, University of Delaware, Newark, Delaware, USA
| | - Bruce D Walker
- 1] Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA. [2] Howard Hughes Medical Institute, Chevy Chase, Maryland, USA
| | - Eric S Rosenberg
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Xu G Yu
- Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
| | - Mathias Lichterfeld
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
| |
Collapse
|
5
|
Huang J, Al-Mozaini M, Rogich J, Carrington MF, Seiss K, Pereyra F, Lichterfeld M, Yu XG. Systemic inhibition of myeloid dendritic cells by circulating HLA class I molecules in HIV-1 infection. Retrovirology 2012; 9:11. [PMID: 22289474 PMCID: PMC3308926 DOI: 10.1186/1742-4690-9-11] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2011] [Accepted: 01/30/2012] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND HIV-1 infection is associated with profound dysfunction of myeloid dendritic cells, for reasons that remain ill-defined. Soluble HLA class I molecules can have important inhibitory effects on T cells and NK cells, but may also contribute to reduced functional properties of professional antigen-presenting cells. Here, we investigated the expression of soluble HLA class I isoforms during HIV-1 infection and assessed their functional impact on antigen-presenting characteristics of dendritic cells. RESULTS Soluble HLA class I molecules were highly upregulated in progressive HIV-1 infection as determined by quantitative Western blots. This was associated with strong increases of intracellular expression of HLA class I isoforms in dendritic cells and monocytes. Using mixed lymphocyte reactions, we found that soluble HLA class I molecules effectively inhibited the antigen-presenting properties of dendritic cells, however, there was no significant influence of HLA class I molecules on the cytokine-secretion properties of these cells. The immunomodulatory effects of soluble HLA class I molecules were mediated by interactions with inhibitory myelomonocytic MHC class I receptors from the Leukocyte Immunoglobulin Like Receptor (LILR) family. CONCLUSIONS During progressive HIV-1 infection, soluble HLA class I molecules can contribute to systemic immune dysfunction by inhibiting the antigen-presenting properties of myeloid dendritic cells through interactions with inhibitory myelomonocytic HLA class I receptors.
Collapse
Affiliation(s)
- Jinghe Huang
- Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Huang J, Yang Y, Al-Mozaini M, Burke PS, Beamon J, Carrington MF, Seiss K, Rychert J, Rosenberg ES, Lichterfeld M, Yu XG. Dendritic cell dysfunction during primary HIV-1 infection. J Infect Dis 2011; 204:1557-62. [PMID: 21969335 DOI: 10.1093/infdis/jir616] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Dendritic cells have critical roles for generating and fine-tuning adaptive immune responses and for regulating immune activity through cytokine secretion. In this study, we analyzed functional properties of dendritic cells in primary human immunodeficiency virus type 1 (HIV-1) infection. We found substantial disarray of the functional properties of myeloid and plasmacytoid dendritic cells in acute HIV-1 infection, which included defective antigen-presenting and cytokine secretion properties and was associated with a distinct surface expression profile of immunomodulatory dendritic cell receptors from the leukocyte immunoglobulin-like receptor family. These data indicate that key functional properties of dendritic cells are compromised during primary HIV-1 infection.
Collapse
Affiliation(s)
- Jinghe Huang
- Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, Carrington MF, Porter LC, Burke PS, Yang Y, Ryan BJ, Liu R, Weiss RH, Pereyra F, Cress WD, Brass AL, Rosenberg ES, Walker BD, Yu XG, Lichterfeld M. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 2011; 121:1549-60. [PMID: 21403397 DOI: 10.1172/jci44539] [Citation(s) in RCA: 144] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2010] [Accepted: 01/19/2011] [Indexed: 12/25/2022] Open
Abstract
Elite controllers represent a unique group of HIV-1-infected persons with undetectable HIV-1 replication in the absence of antiretroviral therapy. However, the mechanisms contributing to effective viral immune defense in these patients remain unclear. Here, we show that compared with HIV-1 progressors and HIV-1-negative persons, CD4+ T cells from elite controllers are less susceptible to HIV-1 infection. This partial resistance to HIV-1 infection involved less effective reverse transcription and mRNA transcription from proviral DNA and was associated with strong and selective upregulation of the cyclin-dependent kinase inhibitor p21 (also known as cip-1 and waf-1). Experimental blockade of p21 in CD4+ T cells from elite controllers resulted in a marked increase of viral reverse transcripts and mRNA production and led to higher enzymatic activities of cyclin-dependent kinase 9 (CDK9), which serves as a transcriptional coactivator of HIV-1 gene expression. This suggests that p21 acts as a barrier against HIV-1 infection in CD4+ T cells from elite controllers by inhibiting a cyclin-dependent kinase required for effective HIV-1 replication. These data demonstrate a mechanism of host resistance to HIV-1 in elite controllers and may open novel perspectives for clinical strategies to prevent or treat HIV-1 infection.
Collapse
Affiliation(s)
- Huabiao Chen
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, Massachusetts, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|